21 recruiting, 11 active not recruiting, 7 completed, 3 terminated. 25 Phase 2, 23 Phase 1, 6 Phase 3, 1 Early Phase 1, 1 Phase 4.
Follow Mixed Phenotype Acute Leukemia: new trials by email Literature Review of Mixed Phenotype Acute Leukemia trials Research Report on Mixed Phenotype Acute Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 1 | Withdrawn | Children's Oncology Group | 2026-09-10 | 2026-05-05 | |
| A Study of Revumenib and Mezigdomide in People With Leukemia Revumenib, Mezigdomide - Leukemia, Acute Leukemia | Phase 1 / Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 52 | 2026-01-16 | 2026-10-20 |
| Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Orca-T - Leukemia, Myeloid, Acute, Myelodysplastic Syndromes | Phase 2 | Recruiting | Orca Biosystems, Inc. | 80 | 2025-12-09 | 2026-07-07 |
| Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT ORCA-T - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 | Recruiting | Stanford University | 24 | 2025-12-01 | 2026-06-23 |
| Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse Decitabine, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Acute Undifferentiated Leukemia | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 36 | 2025-09-23 | 2026-05-15 |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Vironexis Biotherapeutics Inc. | 32 | 2025-05-30 | 2026-10-26 |
| Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation Donor-derived Natural Killer Cell - Acute Myeloid Leukemia, Acute Lymphoblastic T-cell Leukemia | Phase 2 | Recruiting | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 15 | 2025-05-09 | 2025-12-01 |
| Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) Dexamethasone, Vincristine, Daunorubicin - T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 100 | 2024-12-27 | 2026-08-10 |
| Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma Dexamethasone, Vincristine, Daunorubicin - Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma | Phase 4 | Recruiting | St. Jude Children's Research Hospital | 850 | 2024-12-26 | 2026-07-14 |
| Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases Biospecimen Collection, Bone Marrow Aspirate, Cyclophosphamide - Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 54 | 2024-07-23 | 2026-10-26 |
| Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Acute Myeloid Leukemia, Mixed Phenotype Acute Leukemia | Phase 1 | Active not recruiting | Fred Hutchinson Cancer Center | 30 | 2023-12-18 | 2026-07-29 |
| Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma Biospecimen Collection, Calaspargase Pegol, Levocarnitine - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 3 | Active not recruiting | Children's Oncology Group | 440 | 2023-08-24 | 2026-08-21 |
| Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Aspiration, Busulfan - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 66 | 2023-03-15 | 2026-07-30 |
| Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia Blinatumomab - Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia | Phase 3 | Recruiting | Princess Maxima Center for Pediatric Oncology | 160 | 2022-12-15 | 2026-10-19 |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies Tagraxofusp, Fludarabine, Cytarabine - Hematologic Malignancy, AML | Phase 1 | Recruiting | Therapeutic Advances in Childhood Leukemia Consortium | 54 | 2022-11-11 | 2024-12-06 |
| Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia Dasatinib, Methotrexate, Prednisone - B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 1 | Active not recruiting | OHSU Knight Cancer Institute | 20 | 2022-09-02 | 2026-05-06 |
| Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) Orca-Q - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 1 / Phase 2 | Recruiting | University of Florida | 40 | 2022-08-16 | 2026-10-30 |
| Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Orca-T, Standard-of-Care - Acute Myeloid Leukemia, Acute Lymphoid Leukemia | Phase 3 | Active not recruiting | Orca Biosystems, Inc. | 187 | 2022-06-21 | 2026-03-04 |
| Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients Azacitidine, Venetoclax, Flumatinib - Philadelphia Chromosome, Acute Myeloid Leukemia | Phase 2 | Completed | The First Affiliated Hospital of Soochow University | 20 | 2022-05-01 | 2024-04-25 |
Showing 20 of 47. Sign in to see all of them.
Leukemia, Biphenotypic, Acute (47) · Leukemia, Myeloid, Acute (33) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (29) · Myelodysplastic Syndromes (17) · Burkitt Lymphoma (9) · Leukemia (9) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (7) · Blastic Plasmacytoid Dendritic Cell Neoplasm (6) · Hematologic Neoplasms (5) · Leukemia, Myelomonocytic, Chronic (5) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (5) · Hodgkin Disease (4) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma (4) · Myeloproliferative Disorders (4)
Hemic and Lymphatic Diseases (47) · Leukemia, Lymphoid (46) · Lymphatic Diseases (46) · Lymphoproliferative Disorders (46) · Hematologic Diseases (45) · Immune System Diseases (45) · Immunoproliferative Disorders (45) · Neoplasms (45) · Neoplasms by Histologic Type (45) · Leukemia (38) · Leukemia, Myeloid (32) · Bone Marrow Diseases (20) · Lymphoma (14) · Pathological Conditions, Signs and Symptoms (14) · Disease Attributes (13)
Cytarabine (12) · Cyclophosphamide (11) · Specimen Handling (11) · Methotrexate (10) · Whole-Body Irradiation (9) · Calcium Dobesilate (8) · Dexamethasone (8) · Vincristine (8) · fludarabine (8) · Biopsy (6) · Hydrocortisone (6) · Mycophenolic Acid (6) · merphos (6) · venetoclax (6) · Azacitidine (5)
Fred Hutchinson Cancer Center (10) · Children's Oncology Group (5) · Orca Biosystems, Inc. (4) · M.D. Anderson Cancer Center (3) · St. Jude Children's Research Hospital (2) · Syndax Pharmaceuticals (2) · The First Affiliated Hospital of Soochow University (2) · Center for International Blood and Marrow Transplant Research (1) · Central Hospital, Nancy, France (1) · Ehab L Atallah (1) · Federal Research Institute of Pediatric Hematology, Oncology and Immunology (1) · Institut Paoli-Calmettes (1) · Johns Hopkins All Children's Hospital (1) · Kura Oncology, Inc. (1) · Memorial Sloan Kettering Cancer Center (1)
United States (40) · Canada (9) · Australia (8) · France (5) · Puerto Rico (5) · Germany (4) · Italy (4) · New Zealand (4) · Belgium (3) · Israel (3) · Netherlands (3) · Spain (3) · Austria (2) · China (2) · Czechia (2)
Phuong Vo, MD (2) · Abhishek Maiti, MBBS (1) · Adam Lamble, MD (1) · Andrea Biondi (1) · Angela R Smith, M.D. (1) · Ann Dahlberg (1) · Ben K Watkins (1) · Betul Oran (1) · Brenda M. Sandmaier (1) · Cassandra Josephson, MD (1) · Ehab L Atallah, MD (1) · Elias Jabbour (1) · Elizabeth Krakow (1) · Etan Orgel (1) · Heather J Symons (1)
PMID 33741715, PMID 34267079, PMID 41671463, PMID 30335787, PMID 32077361, PMID 32896301, PMID 33027528, PMID 33049057, PMID 33580980, PMID 33792630, PMID 34255353, PMID 34474640, PMID 36175988, PMID 36922593, PMID 38683966, PMID 38867582, PMID 39121437, PMID 39170618, PMID 39362248, PMID 40332046, PMID 40523209, PMID 40535475, PMID 40997296, PMID 41385341, PMID 41619724, PMID 41621809, PMID 42448319, PMID 42616616, PMID 42806776
U10CA180886 (5), P30CA015704 (3), 2017 (1), 2019 (1), P01CA018029 (1), P01CA049605 (1), P01CA078902 (1), U24CA196173 (1), UG1CA189955 (1), UM1CA228823 (1)